Nevertheless, the clinical risk for drug-induced arrhythmia and sudden death may be low, based on an analysis of adverse reactions of drugs with known anti-hERG activity, which showed that the higher the log of the ratio between therapeutic concentrations and the IC50, the lower the risk for cardiac adverse events [21]. This evidence concerns the gene KCNH2 and Arrhythmia.